Today's Trend
Charles River Laboratories International, Inc. (NYSE: CRL) is facing mixed investor signals. Longer-term earnings revisions and a potential vaccine-related collaboration are supportive, while an insider sale and modest reductions to several near-term EPS forecasts may be weighing on sentiment. The stock remains near its 52-week high, which could also encourage profit-taking.
- Long-term earnings outlook improved. Zacks Research raised its EPS forecasts for fiscal 2026 to $11.15 from $10.91, fiscal 2027 to $12.49 from $12.11, and fiscal 2028 to $13.82 from $13.01. Estimates also increased for several future quarters, signaling greater confidence in CRL’s longer-term growth prospects.
- Enterovirus vaccine collaboration could generate future demand. Medigen has partnered with Charles River in an effort to bring an enterovirus vaccine to global markets. The initiative could create additional opportunities for CRL’s contract research, testing, and development services. Medigen links up with Charles River in push to take enterovirus vaccine global
- Recent operating results provide a mixed backdrop. CRL’s latest quarterly EPS of $3.02 exceeded the $2.77 consensus estimate, and revenue reached approximately $1 billion. However, revenue declined 2.7% year over year, while the company’s full-year 2026 EPS guidance remains $11.15-$11.45, close to the analyst consensus.
- Director sold a sizable stake. James C. Foster sold 33,561 shares for about $10.1 million at an average price of $300, reducing his direct ownership by 51.5%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive bearish signal, but the size of the sale may pressure investor sentiment. SEC insider transaction filing
- Some near-term estimates were lowered. Zacks trimmed its EPS forecasts for the third and fourth quarters of 2026, the first quarter of 2027, and the fourth quarter of 2027. These modest cuts suggest near-term uncertainty despite the stronger full-year and longer-term projections.